Q2 Earnings Forecast for OFIX Issued By Barrington Research

Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) - Analysts at Barrington Research issued their Q2 2025 earnings per share estimates for shares of Orthofix Medical in a research note issued to investors on Monday, June 23rd. Barrington Research analyst M. Petusky forecasts that the medical device company will post earnings per share of ($0.72) for the quarter. Barrington Research has a "Strong-Buy" rating and a $16.00 price target on the stock. The consensus estimate for Orthofix Medical's current full-year earnings is ($2.81) per share. Barrington Research also issued estimates for Orthofix Medical's Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($3.04) EPS, Q1 2026 earnings at ($0.83) EPS, Q2 2026 earnings at ($0.67) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($2.34) EPS and FY2027 earnings at ($1.64) EPS.

OFIX has been the subject of a number of other reports. Wall Street Zen upgraded shares of Orthofix Medical from a "sell" rating to a "hold" rating in a report on Saturday, June 14th. JMP Securities restated a "market perform" rating on shares of Orthofix Medical in a report on Friday, June 6th. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $21.50.

Orthofix Medical Trading Up 0.5%

Shares of NASDAQ OFIX traded up $0.05 on Thursday, reaching $11.09. 999,465 shares of the company traded hands, compared to its average volume of 287,156. The stock has a market capitalization of $434.51 million, a PE ratio of -3.01 and a beta of 0.80. Orthofix Medical has a fifty-two week low of $10.24 and a fifty-two week high of $20.73. The company has a current ratio of 2.71, a quick ratio of 1.50 and a debt-to-equity ratio of 0.38. The company has a 50 day moving average of $11.85 and a 200 day moving average of $15.24.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Rhumbline Advisers lifted its position in Orthofix Medical by 1.2% during the fourth quarter. Rhumbline Advisers now owns 54,989 shares of the medical device company's stock valued at $960,000 after buying an additional 661 shares in the last quarter. Invesco Ltd. lifted its position in shares of Orthofix Medical by 1.0% during the fourth quarter. Invesco Ltd. now owns 74,977 shares of the medical device company's stock worth $1,309,000 after purchasing an additional 767 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Orthofix Medical by 4.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,348 shares of the medical device company's stock worth $338,000 after purchasing an additional 836 shares in the last quarter. Gamco Investors INC. ET AL lifted its position in shares of Orthofix Medical by 1.0% during the first quarter. Gamco Investors INC. ET AL now owns 157,100 shares of the medical device company's stock worth $2,562,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Swiss National Bank lifted its position in shares of Orthofix Medical by 2.6% during the fourth quarter. Swiss National Bank now owns 67,600 shares of the medical device company's stock worth $1,180,000 after purchasing an additional 1,700 shares in the last quarter. 89.76% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Orthofix Medical

In other Orthofix Medical news, insider Aviva Mcpherron sold 3,728 shares of Orthofix Medical stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $10.51, for a total transaction of $39,181.28. Following the transaction, the insider now directly owns 46,322 shares of the company's stock, valued at $486,844.22. The trade was a 7.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Massimo Calafiore purchased 10,000 shares of Orthofix Medical stock in a transaction on Friday, May 9th. The shares were acquired at an average cost of $12.54 per share, for a total transaction of $125,400.00. Following the completion of the transaction, the chief executive officer now owns 234,603 shares of the company's stock, valued at $2,941,921.62. This represents a 4.45% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 112,250 shares of company stock worth $1,380,970 and sold 7,620 shares worth $91,168. 1.30% of the stock is owned by insiders.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.